{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+TID&page=13",
    "query": {
      "intervention": "Placebo TID",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 855,
    "total_pages": 86,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+TID&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+TID&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T16:48:52.414Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05164120",
      "title": "Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Belnacasan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MedStar Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2021-12-14",
      "completion_date": "2022-10-11",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-11-20T16:48:52.414Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05164120"
    },
    {
      "nct_id": "NCT01178827",
      "title": "Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "trospium chloride",
          "type": "DRUG"
        },
        {
          "name": "oxybutynin IR",
          "type": "DRUG"
        },
        {
          "name": "oxybutynin IR placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2010-08",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2016-02-26",
      "last_synced_at": "2026-11-20T16:48:52.414Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01178827"
    },
    {
      "nct_id": "NCT02454608",
      "title": "Trial of Verapamil in Chronic Rhinosinusitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sinusitis",
        "Nasal Polyps"
      ],
      "interventions": [
        {
          "name": "Verapamil HCl",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Benjamin Bleier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 29,
      "start_date": "2015-05",
      "completion_date": "2017-05",
      "has_results": true,
      "last_update_posted_date": "2018-06-14",
      "last_synced_at": "2026-11-20T16:48:52.414Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02454608"
    },
    {
      "nct_id": "NCT02794467",
      "title": "Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenomyosis"
      ],
      "interventions": [
        {
          "name": "Epelsiban",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2016-07",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2017-01-18",
      "last_synced_at": "2026-11-20T16:48:52.414Z",
      "location_count": 13,
      "location_summary": "Washington D.C., District of Columbia • West Palm Beach, Florida • Champaign, Illinois + 10 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Champaign",
          "state": "Illinois"
        },
        {
          "city": "Mandeville",
          "state": "Louisiana"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02794467"
    },
    {
      "nct_id": "NCT01482403",
      "title": "A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Copegus",
          "type": "DRUG"
        },
        {
          "name": "Pegasys",
          "type": "DRUG"
        },
        {
          "name": "boceprevir",
          "type": "DRUG"
        },
        {
          "name": "mericitabine",
          "type": "DRUG"
        },
        {
          "name": "mericitabine placebo",
          "type": "DRUG"
        },
        {
          "name": "boceprevir placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2011-11",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2016-08-05",
      "last_synced_at": "2026-11-20T16:48:52.414Z",
      "location_count": 7,
      "location_summary": "Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more",
      "locations": [
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01482403"
    },
    {
      "nct_id": "NCT07635862",
      "title": "Clinical Trial Evaluating the Effects of Ganaxolone in Children With Autism",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism in Children",
        "Autistic Disorder in Children and Adolescents",
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Ganaxolone (Ztalmy)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 66,
      "start_date": "2027-01-01",
      "completion_date": "2030-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-20T16:48:52.414Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07635862"
    },
    {
      "nct_id": "NCT00159861",
      "title": "The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "Sildenafil citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 267,
      "start_date": "2003-07",
      "completion_date": "2006-01",
      "has_results": true,
      "last_update_posted_date": "2021-02-01",
      "last_synced_at": "2026-11-20T16:48:52.414Z",
      "location_count": 33,
      "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 21 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00159861"
    },
    {
      "nct_id": "NCT00985205",
      "title": "The RE-ENERGIZE Study: RandomizEd Trial of ENtERal Glutamine to minimIZE Thermal Injury",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Burns"
      ],
      "interventions": [
        {
          "name": "Enteral Glutamine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Daren K. Heyland",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1201,
      "start_date": "2010-12",
      "completion_date": "2021-12",
      "has_results": false,
      "last_update_posted_date": "2021-12-30",
      "last_synced_at": "2026-11-20T16:48:52.414Z",
      "location_count": 27,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00985205"
    },
    {
      "nct_id": "NCT00835770",
      "title": "BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing-Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "dimethyl fumarate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "58 Years",
        "sex": "ALL",
        "summary": "19 Years to 58 Years"
      },
      "enrollment_count": 1736,
      "start_date": "2009-02-03",
      "completion_date": "2019-11-08",
      "has_results": true,
      "last_update_posted_date": "2020-12-31",
      "last_synced_at": "2026-11-20T16:48:52.414Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00835770"
    },
    {
      "nct_id": "NCT00813826",
      "title": "Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postherpetic Neuralgia"
      ],
      "interventions": [
        {
          "name": "SLC022",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Solace Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 204,
      "start_date": "2009-01",
      "completion_date": "2009-11",
      "has_results": false,
      "last_update_posted_date": "2009-07-30",
      "last_synced_at": "2026-11-20T16:48:52.414Z",
      "location_count": 19,
      "location_summary": "Sierra Vista, Arizona • Mission Viejo, California • Orlando, Florida + 16 more",
      "locations": [
        {
          "city": "Sierra Vista",
          "state": "Arizona"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00813826"
    }
  ]
}